Skip to main content
YECO logo

EV Biologics, Inc. (YECO) Stock Price & Analysis

EV Biologics, Inc. (YECO) — price $0.0004 (0.00%), as of the Nov 18, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0004 $0.00 (0.00%)

EV Biologics, Inc. · YECO

Yulong Eco-Materials Limited, operating as EV Biologics, Inc., is a biotechnology firm headquartered in Cheyenne, US. The company specializes in developing extracellular vesicles (EVs) for diagnostics and therapeutics, alongside human mesenchymal and other stem cell-derived products for cosmetic and biopharmaceutical applications, leveraging its proprietary multifunctional EV platform.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0004
Change on the day0.00%
52-week range$0.0001 – $0.1056
Shares traded on the day10.0K

Price & events

Other perspectives

Council score for EV Biologics (YECO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Weak

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is EV Biologics (YECO), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. EV Biologics, Inc. (YECO) is the company analyzed here. It employs 284 people and is led by Daniel S. McKinney. In Q3 FY2025 it reported revenue of $9,000 and net income of -$48,290.

2 · Latest results

What do the latest results show for EV Biologics (YECO)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $9,000.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$9,000-$48,290-$0.0047 (diluted)
Q1 FY2025$48,000$4,709$0.0005 (diluted)
Q4 FY2024$40,344$7,510$0.0010 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for EV Biologics (YECO)?

Short answer · as of

The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 3.11.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held YECO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported YECO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About YECO

These answers are editorial: 1 of these 1 answer is drawn from the YECO research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.

What are the key growth opportunities for YECO in healthcare?

YECO's primary growth opportunities in healthcare stem from its innovative extracellular vesicle (EV) platform and its stem cell-derived products. One significant area is the advancement of EV-based therapeutics and vaccines.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.